用于非小细胞肺癌和眼部转移的酪氨酸激酶抑制剂：疾病复发还是一种新情况？
Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?
作者信息
Zarogoulidis Paul, Lampaki Sofia, Chinelis Panos, Lazaridis George, Baka Sofia, Rapti Aggeliki
机构信息
Pulmonary Department, Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Oncology Department, G. Papageorgiou University General Hospital, Thessaloniki, Greece.
出版信息
Med Hypothesis Discov Innov Ophthalmol. 2016 Winter;5(4):132-135.
Abstract
Lung cancer is still diagnosed during the advanced stage of the disease and most patients do not have the opportunity for surgical treatment, despite the new diagnostic equipment that has been made available in recent years, such as the radial and linear endobronchial ultrasound (EBUS) and electromagnetic fiberoptic bronchoscopy. However, novel targeted therapies with second generation tyrosine kinase inhibitors and immunotherapy are available. In this commentary, we will focus on eye metastasis after initiation of tyrosine kinase inhibitors due to epidermal growth factor mutation of lung cancer adenocarcinoma.
摘要
尽管近年来出现了新的诊断设备，如径向和线性支气管内超声（EBUS）以及电磁纤维支气管镜，但肺癌仍在疾病晚期才被诊断出来，大多数患者没有机会接受手术治疗。然而，有第二代酪氨酸激酶抑制剂和免疫疗法等新型靶向治疗方法。在这篇评论中，我们将聚焦于因肺腺癌表皮生长因子突变而开始使用酪氨酸激酶抑制剂后出现的眼部转移。
相似文献
1
Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?
Med Hypothesis Discov Innov Ophthalmol. 2016 Winter;5(4):132-135.
2
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
3
Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment.
BMC Pulm Med. 2016 Jul 26;16(1):106. doi: 10.1186/s12890-016-0268-3.
4
Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
Respirology. 2016 May;21(4):718-26. doi: 10.1111/resp.12737. Epub 2016 Jan 27.
5
Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
Cancer Cytopathol. 2018 Oct;126(10):860-871. doi: 10.1002/cncy.22053. Epub 2018 Oct 6.
6
Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer.
Lung Cancer Manag. 2020 Jan 16;8(4):LMT20. doi: 10.2217/lmt-2019-0008.
7
Recent advances in diagnostic bronchoscopy.
J Thorac Dis. 2016 Dec;8(12):3808-3817. doi: 10.21037/jtd.2016.12.70.
8
Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS).
Endoscopy. 2015 Jun;47(6):545-59. doi: 10.1055/s-0034-1392040. Epub 2015 Jun 1.
9
Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies.
BMC Pulm Med. 2017 Dec 6;17(1):175. doi: 10.1186/s12890-017-0514-3.
10
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
引用本文的文献
1
Cell Culture Model Evolution and Its Impact on Improving Therapy Efficiency in Lung Cancer.
Cancers (Basel). 2023 Oct 15;15(20):4996. doi: 10.3390/cancers15204996.
2
EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.
J Cancer Res Clin Oncol. 2022 Feb;148(2):309-319. doi: 10.1007/s00432-021-03800-6. Epub 2021 Oct 18.
3
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
Biomol Ther (Seoul). 2022 Jan 1;30(1):19-27. doi: 10.4062/biomolther.2021.047.
本文引用的文献
1
Biomarkers along the continuum of care in lung cancer.
Scand J Clin Lab Invest Suppl. 2016;245:S40-5. doi: 10.1080/00365513.2016.1208446.
2
Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women. An updated review and meta-analysis.
Inhal Toxicol. 2016 Aug;28(10):431-54. doi: 10.1080/08958378.2016.1210701.
3
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Medicine (Baltimore). 2016 Aug;95(31):e4176. doi: 10.1097/MD.0000000000004176.
4
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria.
Q J Nucl Med Mol Imaging. 2016 Sep;60(3):264-73. Epub 2014 May 9.
5
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Oncotarget. 2016 Jul 26;7(30):48059-48069. doi: 10.18632/oncotarget.10351.
6
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far.
Ther Clin Risk Manag. 2016 May 24;12:807-16. doi: 10.2147/TCRM.S92996. eCollection 2016.
7
Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?
Br J Radiol. 2016 Sep;89(1065):20160113. doi: 10.1259/bjr.20160113. Epub 2016 Jun 20.
8
Determination of and mutational status in Greek non-small-cell lung cancer patients.
Oncol Lett. 2015 Oct;10(4):2176-2184. doi: 10.3892/ol.2015.3600. Epub 2015 Aug 12.
9
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Onco Targets Ther. 2015 Oct 13;8:2915-21. doi: 10.2147/OTT.S91627. eCollection 2015.
10
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Medicine (Baltimore). 2015 Oct;94(41):e1739. doi: 10.1097/MD.0000000000001739.
Zotero 插件